Drugs / TL-895
Trials 8 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT04419623 | Jul → Sep 2020 | COVID-19, carcinoma, hematopoietic and lymphoid system neoplasm | Telios Pharma, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT03297983 | Oct → Dec 2017 | — | Merck KGaA, Darmstadt, Germany | Completed | No outcome recorded |
| Phase 1/24 trials | ||||||
| Phase 1/2 | NCT05280509 | Jun 2022 → Oct 2025 overdue | myelofibrosis, primary myelofibrosis | Telios Pharma, Inc. | Recruiting | No outcome recorded |
| Phase 1/2 | NCT04669067 | Mar 2021 → Nov 2024 | acute myeloid leukemia | Telios Pharma, Inc. | Unknown | No outcome recorded |
| Phase 1/2 | NCT04640532 | Nov 2020 → May 2022 | myelofibrosis, primary myelofibrosis | Kartos Therapeutics, Inc. | Unknown | No outcome recorded |
| Phase 1/2 | NCT02825836 | Aug 2016 → Dec 2024 | chronic lymphocytic leukemia/small lymphocytic lymphoma | Telios Pharma, Inc. | Unknown | No outcome recorded |
| Phase 22 trials | ||||||
| Phase 2 | NCT04878003 | Apr 2021 → May 2024 | myelofibrosis, primary myelofibrosis | Kartos Therapeutics, Inc. | Unknown | No outcome recorded |
| Phase 2 | NCT04655118 | Oct 2020 → Jun 2025 | indolent systemic mastocytosis, myelofibrosis | Telios Pharma, Inc. | Unknown | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 8 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | TL-895 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05280509 ↗ |
| Known as | M7583 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03297983 ↗ |
| Action | Inhibit | “tyrosine kinase inhibitor” NCT02825836 ↗ |
| Modality | Small molecule | “TL-895 is an experimental tyrosine kinase inhibitor drug taken by mouth.” NCT04655118 ↗ |
| Route | Oral | “taken by mouth” NCT02825836 ↗ |